One of the main factors determining therapeutic antibodies’ half-life is the interaction between the antibody’s Fc region and ...

Annexon has completed enrollment in its phase 3 ARCHER II trial of vonaprument (formerly ANX007) for dry age-related macular ...

The drug is indicated for the treatment rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic ...

DelveInsight's CD40/CD40L Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

The triggering receptor expressed on myeloid cells 2 (TREM2) plays a pivotal role in the activation of myeloid cells and is ...

A new study done by scientists in Switzerland and Sweden investigated the use of automated systems to develop multispecific antibodies.

Lupin & Zentiva ink licensing and supply agreement for commercializing biosimilar Certolizumab Pegol: Our Bureau, Mumbai Wednesday, July 9, 2025, 16:20 Hrs [IST] Global Pharma maj ...

Zentiva Group has entered a licence and supply agreement with Lupin for the commercialisation of latter’s biosimilar Certolizumab Pegol.

Measles is one of 100 viruses that the team at VUMC is systematically making antibodies for by using single-cell sequencing — ...

Zentiva Group and global pharmaceutical company Lupin Limited, have entered into a license and supply agreement for ...

Pharma major Lupin has signed a USD 50 million agreement with a European pharmaceutical company. Lupin has entered into a license and supply agreement to commercialize its biosimilar Certolizumab ...

Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...